Summary & Overview
HCPCS Level II J0889: Daprodustat, Oral 1 mg (ESRD on Dialysis)
HCPCS Level II code J0889 identifies daprodustat, oral, 1 mg, for patients with end-stage renal disease (ESRD) on dialysis. This drug-specific HCPCS code matters nationally because it enables standardized billing for a targeted oral therapy for anemia management in the growing dialysis population, affecting pharmacy claims, clinical protocols, and payer coverage decisions across public and commercial plans. Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what J0889 represents clinically and operationally, an outline of payer coverage considerations, and the types of benchmarks and policy elements typically relevant to drug-specific HCPCS codes. The publication covers national reimbursement benchmarks and common billing scenarios for outpatient dialysis settings and pharmacy dispensing, highlights applicable coverage pathways used by major payers, and summarizes clinical context for daprodustat in anemia of CKD for patients on dialysis. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0889 represents daprodustat, oral, 1 mg, indicated for patients with end-stage renal disease (ESRD) on dialysis. This billing code denotes an oral pharmaceutical agent used to manage anemia associated with chronic kidney disease in patients receiving dialysis.
Service Type: Oral medication administration (pharmacy-dispensed drug)
Typical Site of Service: Outpatient dialysis centers and pharmacy dispensing for patients on dialysis
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with end-stage renal disease (ESRD) on maintenance hemodialysis who has anemia of chronic kidney disease requiring erythropoiesis-stimulating therapy. The patient attends a dialysis clinic or outpatient nephrology infusion clinic for routine management. Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia in patients with ESRD on dialysis. Clinical workflow: the nephrologist documents hemoglobin level, iron studies, and relevant comorbidities; confirms indication for treatment and dosing; prescribes J0889 for the appropriate oral strength and quantity; the dialysis clinic pharmacy dispenses medication and documents administration or provision; nursing documents patient education, adherence counseling, and any adverse effects; routine labs are scheduled to monitor hemoglobin, ferritin, transferrin saturation, and blood pressure. Billing for J0889 occurs under the HCPCS Level II code for daprodustat with service typically rendered in an outpatient dialysis facility or outpatient clinic associated with ESRD care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When additional work beyond usual is required to manage complex dosing evaluation or extensive documentation related to therapy |